Regulus Therapeutics (NASDAQ:RGLS) Posts Quarterly Earnings Results, Hits Expectations

Regulus Therapeutics (NASDAQ:RGLS) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20), Zacks reports.

Regulus Therapeutics Price Performance

RGLS stock traded down $0.10 during trading hours on Thursday, reaching $1.38. The stock had a trading volume of 193,056 shares, compared to its average volume of 536,987. The stock has a 50-day simple moving average of $1.29 and a 200 day simple moving average of $1.47. Regulus Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $3.00. The stock has a market capitalization of $90.39 million, a PE ratio of -1.29 and a beta of 1.41.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Regulus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $10.80.

Insider Transactions at Regulus Therapeutics

In other news, insider Preston Klassen sold 31,445 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $39,620.70. Following the completion of the sale, the insider now owns 36,055 shares in the company, valued at approximately $45,429.30. This trade represents a 46.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Christopher Ray Aker sold 38,547 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,569.22. Following the completion of the transaction, the vice president now owns 54,634 shares in the company, valued at approximately $68,838.84. This trade represents a 41.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 223,998 shares of company stock worth $282,237 in the last ninety days. Insiders own 4.35% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.